Surrozen, Inc./DE Operating Lease, Liability, Noncurrent
Surrozen, Inc./DE (SRZN) had Operating Lease, Liability, Noncurrent of $4.33 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-06
- 2026-06-30: Operating Lease, Liability, Noncurrent $4.33M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $4.85M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $5.35M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $5.84M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $4.33M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $4.85M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $5.35M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $5.84M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $6.32M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $6.78M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $6.64M 10-K · filed 2026-03-23 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-06 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-12 |
| 2024-03-31 | $223.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $882.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.53M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $2.16M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $2.78M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $3.38M 10-K · filed 2024-04-10 |
| 2022-09-30 | $3.96M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $4.53M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $5.07M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $5.60M 10-K · filed 2023-03-31 |
| 2021-09-30 | $6.06M 10-Q · filed 2021-11-15 |
| 2020-12-31 | $7.49M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |